214 related articles for article (PubMed ID: 26797042)
1. Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease.
Echeverria V; Yarkov A; Aliev G
Prog Neurobiol; 2016 Sep; 144():142-57. PubMed ID: 26797042
[TBL] [Abstract][Full Text] [Related]
2. Nicotinic Cholinergic Mechanisms in Alzheimer's Disease.
Shen J; Wu J
Int Rev Neurobiol; 2015; 124():275-92. PubMed ID: 26472533
[TBL] [Abstract][Full Text] [Related]
3. Tropisetron and its targets in Alzheimer's disease.
Hashimoto K
Expert Opin Ther Targets; 2015 Jan; 19(1):1-5. PubMed ID: 25399811
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update.
Hoskin JL; Al-Hasan Y; Sabbagh MN
Nicotine Tob Res; 2019 Feb; 21(3):370-376. PubMed ID: 30137524
[TBL] [Abstract][Full Text] [Related]
5. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists.
Kroker KS; Moreth J; Kussmaul L; Rast G; Rosenbrock H
Brain Res Bull; 2013 Jul; 96():28-38. PubMed ID: 23639920
[TBL] [Abstract][Full Text] [Related]
6. On the interaction of β-amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer's disease.
Oz M; Lorke DE; Yang KH; Petroianu G
Curr Alzheimer Res; 2013 Jul; 10(6):618-30. PubMed ID: 23627750
[TBL] [Abstract][Full Text] [Related]
7. Neuroinflammation Modulation via α7 Nicotinic Acetylcholine Receptor and Its Chaperone, RIC-3.
Mizrachi T; Vaknin-Dembinsky A; Brenner T; Treinin M
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684720
[TBL] [Abstract][Full Text] [Related]
8. The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease.
Skok M; Lykhmus O
Curr Pharm Des; 2016; 22(14):2035-49. PubMed ID: 26818865
[TBL] [Abstract][Full Text] [Related]
9. Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.
Vallés AS; Borroni MV; Barrantes FJ
CNS Drugs; 2014 Nov; 28(11):975-87. PubMed ID: 25248971
[TBL] [Abstract][Full Text] [Related]
10. N-Stearoylethanolamine protects the brain and improves memory of mice treated with lipopolysaccharide or immunized with the extracellular domain of α7 nicotinic acetylcholine receptor.
Lykhmus O; Uspenska K; Koval L; Lytovchenko D; Voytenko L; Horid'ko T; Kosiakova H; Gula N; Komisarenko S; Skok M
Int Immunopharmacol; 2017 Nov; 52():290-296. PubMed ID: 28963942
[TBL] [Abstract][Full Text] [Related]
11. Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.
Sadigh-Eteghad S; Talebi M; Mahmoudi J; Babri S; Shanehbandi D
Neuroscience; 2015 Jul; 298():81-93. PubMed ID: 25881725
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective and Neurotoxic Implications of α7 Nicotinic Acetylcholine Receptor and Aβ Interaction: Therapeutic Options in Alzheimer's Disease.
Farhat SM; Ahmed T
Curr Drug Targets; 2017; 18(13):1537-1544. PubMed ID: 27719660
[TBL] [Abstract][Full Text] [Related]
13. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease.
Oddo S; Caccamo A; Green KN; Liang K; Tran L; Chen Y; Leslie FM; LaFerla FM
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):3046-51. PubMed ID: 15705720
[TBL] [Abstract][Full Text] [Related]
14. Temporal changes of CD68 and α7 nicotinic acetylcholine receptor expression in microglia in Alzheimer's disease-like mouse models.
Matsumura A; Suzuki S; Iwahara N; Hisahara S; Kawamata J; Suzuki H; Yamauchi A; Takata K; Kitamura Y; Shimohama S
J Alzheimers Dis; 2015; 44(2):409-23. PubMed ID: 25352454
[TBL] [Abstract][Full Text] [Related]
15. Flavonoids as positive allosteric modulators of α7 nicotinic receptors.
Nielsen BE; Bermudez I; Bouzat C
Neuropharmacology; 2019 Dec; 160():107794. PubMed ID: 31560909
[TBL] [Abstract][Full Text] [Related]
16. Unbalanced Regulation of α7 nAChRs by Ly6h and NACHO Contributes to Neurotoxicity in Alzheimer's Disease.
Wu M; Liu CZ; Barrall EA; Rissman RA; Joiner WJ
J Neurosci; 2021 Oct; 41(41):8461-8474. PubMed ID: 34446574
[TBL] [Abstract][Full Text] [Related]
17. Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: α7-nAChR agonists in human clinical trials.
Russo P; Del Bufalo A; Frustaci A; Fini M; Cesario A
Curr Pharm Des; 2014; 20(38):6014-21. PubMed ID: 24641224
[TBL] [Abstract][Full Text] [Related]
18. Role of Alpha-7-Nicotinic Acetylcholine Receptor in Alzheimer's Disease.
Singh S; Agrawal N; Goyal A
CNS Neurol Disord Drug Targets; 2024; 23(3):384-394. PubMed ID: 37366362
[TBL] [Abstract][Full Text] [Related]
19. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
Nikiforuk A; Kos T; Hołuj M; Potasiewicz A; Popik P
Neuropharmacology; 2016 Feb; 101():389-400. PubMed ID: 26232639
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
